logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

EHA 2020 – Combination of venetoclax and navitoclax explored in pretreated patients with ALL

A phase 1 study with heavily pretreated patients with relapsed or refractory ALL reports promising response rates for the combination of 2 BCL-2-inhibitors.